TC BioPharm Receives Extension from Nasdaq Hearings Panel to Regain Compliance With Listing Rule 5550(b)(2)PRNewsWire • 03/16/23
TC BioPharm Announces Publication of Paper in AML Research Highlighting the Company's Development of Allogeneic Gamma-Delta T cell TherapiesPRNewsWire • 02/21/23
TC BioPharm Announces Successful Dosing of Final Patient in ACHIEVE Safety CohortPRNewsWire • 02/07/23
TC BioPharm Announces Hiring of Chief Clinical Officer Bree Harlin to Lead Global Clinical DivisionPRNewsWire • 01/30/23
TC BioPharm Receives Notice of Non-compliance with NASDAQ's Listing Rule 5550(b)(1)PRNewsWire • 01/19/23
TC BioPharm Announces Strategic Collaboration to Advance Gamma Delta T Cells in OncologyPRNewsWire • 01/17/23
TC BioPharm Reports First Half 2022 Financial Results and Provides Shareholder UpdatePRNewsWire • 12/12/22
TC BioPharm Begins Dosing Phase 2B Clinical Study Evaluating its Lead Compound, OmnImmune®, in Patients with Acute Myeloid LeukemiaPRNewsWire • 11/22/22
TC BioPharm Announces Key Additions to Scientific Advisory Board, Expanding Cell Therapy ExpertisePRNewsWire • 10/26/22
TC BioPharm Receives MHRA Approval for 18-Month Extrapolated Shelf-Life of Allogeneic Cell Therapy Product, OmnImmune®PRNewsWire • 09/13/22
TC BioPharm to Present at the H.C. Wainwright 24th Annual Global Investment ConferencePRNewsWire • 08/22/22
TC BioPharm CEO, Bryan Kobel to Speak at the "Innovating Cell and Gene Therapy Quality Control Conference 2022"PRNewsWire • 07/08/22